 |
|
 |
 |
|
Fig. 2A. Lymph node with chronic
lymphatic lekaemia (CLL) stained for CD20. A uniform strong
membraneous staining is seen. |
Fig. 2B. Colon with Burkitt lymphoma
stained for CD20. A uniform strong staining is seen. The crypts are
negative. |
 |
 |
|
Fig. 2C. Angioimmunoblastic T-cell
lymphoma stainedfor CD20. The strongly stained cells are B-cells
whilethe weakly stained cells are the neoplastic T-cels. |
Fig. 2D. Diffuse large B-cell lymphoma
stained for CD20. before rituximab treatment was given (compare with
Fig. 2E). |
 |
 |
|
Fig. 2E. Diffuse large B-cell lymphoma
stained for CD20 after treatment with rituximab. All the lymphoma
cells are negative (compare with Fig. 2c). |
Fig. 2F. Diffuse large B-cell lymphoma
stained for CD79a after treatment with rituximab. The lymphoma cells
can be detected as B-cells based on other characteristics (compare
with Fig. 2E). |
